Table 5.

Review of previous studies examining MRI/MRCP

Study	Imaging	n	Subject Criteria	Findings
Al-Sukhni 2012¹⁸	MRI/MRCP (without contrast)	262	FDR or SDR of a PC patient in a FPC family, FDR of individuals with PC + other primary cancers, p16, STK11, or BRCA mutation carriers, or PJS or Hereditary Pancreatitis patients	3 adenocarcinomas, 15 BD-IPMNs, 2 PanIN 1–2 lesions, 22 main duct dilations, 1 neuorendocrine tumor, 7 extrapancreatic lesions
Ludwig 2011¹⁹	MRCP	109 (98 had MRCP)	1+ FDR with PC before age 50 years, 2+ relatives with PC (one of whom is a FDR), 3+ SDR with PC, or BRCA mutation carrier with 1+ relatives with PC	1 adenocarcinoma, 3 MD-IPMNs, 2 BD-IPMNs, 1 PanIN2, 1 PanIN3, 1 SCA w/PanIN1 cells
Vasen 2011²⁰	MRI/MRCP	79	p16-Leiden mutation carriers	7 adenocarcinomas, 9 duct ectasias
Verna 2010²¹	EUS and/or MRI/MRCP + Ca19-9/OGTT	23 (# HRIs who got MRI/MRCP)	≥3 FDR, SDR, or third-degree relatives with PC, ≥2 FDRs with PC, 1 FDR and 1 SDR with PC with 1 at <55 years old, or Genetic syndrome with PC	2 adenocarcinomas, 1 ‘other cyst,’1 ‘isolated PD irregularity, at least 1 extrapancreatic neoplasm
Canto 2012⁵	MRI/MRCP	216	PJS patients, FBOC patients with ≥1 affected FDR or SDR with PC, or Relatives of patients with FPC with ≥1 affected FDR	1 solid mass, 72 cystic masses, 5 main duct dilations, 29 branch duct dilations

Data in this table are taken from the screening of high-risk pts with MRI/MRCP, not the entire study

FDR first-degree relative, SDR second-degree relative, PC pancreatic cancer, FPC familial pancreatic cancer, PJS Peutz-Jehgers Syndrome, BD-IPMNs branch duct intraductal papillary mucinous neoplasms, Pan-IN pancreatic intraepithelial, MD-IPMNs main duct intraductal papillary mucinous neoplasms, SCA Serous cystadenoma, OGTT Oral glucose tolerance test, HRIs high-risk individuals, PD pancreatic duct, FBOC Familial breast and ovarian cancer